Research Article: Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib Plus Humanized Programmed Death Receptor- in Patients with High-Risk Advanced Hepatocellular Carcinoma: A Real-World Study
Introduction:
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most common cause of cancer-related deaths worldwide. , About % of cases of HCC occur in Asia, and >% occur in China. Most patients present advanced, unresectable disease, with a poor -year survival probability of approximately –%. ,
Read more